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Abstract: There is a growing body of evidence that implicates the herpes simplex type 1 virus 
(HSV-1) in the development of Alzheimer’s dementia (AD). HSV-1 has been found to be present 
in the cerebrum of the great majority of older adults, and in many of the same areas of the brain 
that are affected by AD. When active, the virus may contribute to the formation of the neuro-
fibrillary tangles and amyloid plaques characteristic of AD. Like AD, HSV-1 encephalitis may 
cause long term memory loss. HSV-1 replication is suppressed in lysine-rich/arginine – poor 
environments, and population studies suggest that diets high in lysine and low in arginine may 
be associated with lower rates of AD. There are no prospective studies of the efficacy of lysine 
supplementation to prevent or reduce the incidence of AD. Supplementation with adequate doses 
of lysine could prevent the development of AD.
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Introduction
Progress toward an effective treatment to prevent Alzheimer’s dementia (AD), or to 
retard its progression, has proven to be exceedingly elusive. In the last year alone, three 
promising drugs have failed to show clinical efficacy (bapineuzumab, latrepirdine, 
and semagacestat). Although current strategies directed at reducing or eliminating the 
production of amyloid plaques, or at eliminating plaques already produced, may finally 
lead to a solution, the time may have come to examine alternative approaches.
In 1982, Ball proposed that the herpes simplex type 1 virus (HSV-1) might be 
involved in the pathogenesis of AD and “degenerative” lesions of the normal aged 
human brain.1 Ball noted that HSV-1 was well known to establish a lifelong presence in 
the trigeminal nucleus, and that the trigeminal nucleus has projections into the mesial 
temporal (limbic) areas of the brain that are affected in AD and in herpes encephalitis. 
A reactivated virus might therefore have access “downstream” to manifest as herpes 
labialis (“cold sores”), and “upstream” into the limbic regions of the brain.
In recent years, several researchers have made progress in developing what might 
be called a strong circumstantial case for Ball’s hypothesis. Among these is the labo-
ratory of Dr Itzhaki who has studied HSV-1 and AD for nearly 20 years. In a recent 
review article she summarizes some of the findings of her group and others,2 noting 
that 1) HSV-1 DNA has been found in a high (90%) percentage of the brains of elderly 
people, including the brains of AD patients; 2) that HSV-1 can persist in an active 
or inactive state throughout a host subject’s lifetime; 3) that intrathecal antibodies 
to HSV-1 have been identified in the cerebral spinal fluid (CSF) of AD patients and 





4) that HSV-1 infection is associated with inflammation, 
and several mediators of inflammation have been identified 
that are common to both HSV-1 infection and AD;4,5 5) that 
HSV-1 may contribute directly to the formation of amyloid 
plaques and neurofibrillary tangles, the histologic hallmarks 
of AD;6–9 6) that HSV-1 infection leads to accumulation of 
cholesterol in infected cells, which has been found to be 
associated with the formation of amyloid;10,11 7) that acute 
HSV- 1 cerebral infection (encephalitis) affects the temporal 
and frontal cortices of the brain, but not the occipital lobes, 
which are many of the same areas affected in AD;12 8) that the 
long term sequelae of HSV-1 encephalitis include memory 
loss,12 a clinical hallmark of AD; and 9) that HSV-1 confers 
a high risk of AD in patients who carry the APOE-4 allele, 
a well-established genetic risk factor for AD.13 Interestingly, 
APOE-4 is also a risk factor for development of herpes labia-
lis, a peripheral manifestation of HSV-1 reactivation.14
These and other findings demonstrate that HSV-1 is 
present in relevant cerebral regions and capable of causing 
the amyloid plaques, neurofibrillary tangles, inflammatory 
changes, and memory loss characteristic of AD. Although 
they do not constitute proof of causation, they are consistent 
with the hypothesis that HSV-1 may be responsible for at 
least some cases of AD. However, if the virus is present in 
such a high percentage of the general population, the ques-
tion must arise, why is AD primarily a disease of the elderly? 
Why do many elderly develop the disease, but a majority 
do not? Or to put it another way, what are the changes that 
occur in later age in some people that are conducive to the 
reactivation of the virus and the subsequent development 
of AD? Two factors will be considered in the text below: 
the lysine to arginine ratio in the brain, and activity of the 
immune system.
Lysine treatment of herpes labialis
It has been known since 1968 that HSV-1 requires arginine 
for replication,15 and that lysine inhibits HSV-1 replication 
by competing with arginine.16 These findings led to the use 
of lysine as a treatment for the common condition known 
as herpes labialis which, as noted above, is known to be 
caused by HSV-1. Seven randomized, double-blind, placebo-
controlled studies have examined the effectiveness of lysine 
in preventing outbreaks of herpes labialis and reducing the 
severity of outbreaks that do occur. Six of these studies found 
lysine to be effective in preventing or decreasing outbreaks, 
and only two found that lysine reduced the severity of out-
breaks. The first study, conducted in 1978, employed a dosage 
of 500 mg/day of lysine and found it to be ineffective.17 
A 1984 study specified 1,000 mg of lysine, given once a day, 
and also measured serum lysine levels. Lysine was found to 
be effective in reducing outbreaks when serum lysine con-
centration was greater than 165 nmol/mL, but not when it 
was less than this.18 Another study, also published in 1984, 
found that a dosage of 1,248 mg/day was effective in reducing 
outbreak frequency, but that 624 mg/day was ineffective.19 
A 1987 study studied lysine 1,000 mg three times a day, and 
found it to be effective in reducing both the frequency and 
severity of attacks.20
It seems beyond question, then, that lysine in sufficient 
concentrations relative to arginine suppresses reactivation of 
HSV-1 in vivo, at least in so far as it is manifested peripher-
ally as herpes labialis. It has been shown to be effective in 
reducing frequency of herpes labialis attacks, and possibly 
the severity of attacks, when given in dosages of at least 
1,500 mg/day in divided doses.
Lysine: arginine in the CSF
Lysine is an essential amino acid, and the most highly con-
served of all amino acids. The average adult diet supplies 
6–10 g/day of lysine. Following absorption, it is transported 
across the blood–brain barrier by a basic amino acid carrier, 
and competes with arginine for transport. There are very few 
reports about this transporter, although there is evidence that 
the cat-1 transporter is responsible for the movement of lysine 
and arginine across the blood–brain barrier.21 From the point 
of view of the current discussion, this is a pivotal point: the 
relative concentrations of lysine and arginine will depend 
on their transport across the blood–brain barrier, as well as 
their rates of efflux from the central nervous system. Lysine, 
unlike arginine, as an essential amino acid, cannot be made 
within the central nervous system. If lysine is not consumed 
in the diet in adequate quantities relative to arginine, or if it 
is not transported across the blood–brain barrier in adequate 
quantities relative to arginine, conditions may evolve in the 
central nervous system that are favorable for the reactivation 
of HSV-1.
It is not known whether activity of the lysine transporter 
declines with age. It is known, however, that CSF levels of 
amino acids are not constant, and may change with disease 
states. For example, CSF amino acid levels, including lysine 
and arginine, vary in patients with Parkinson’s disease rela-
tive to normal controls.22
It is known that older age is associated with dietary 
changes, and these may reduce the amount of lysine available 
to be transported. Many factors have been proposed to explain 
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advancing age, and dietary choices move away from protein 
and energy dense foods such as meats, and towards foods that 
are less protein and energy dense, such as grains.23 This is a 
change, in general, from foods that have a favorable lysine to 
arginine ratio to foods that do not. As a result of diminished 
total caloric intake, and a change to foods with less lysine 
relative to arginine, it is likely that over time an environment 
more favorable to reactivation of HSV-1 evolves.
There are, then, at least two factors in older age that might 
shift the lysine to arginine ratio in favor of arginine, and 
thereby favor the reactivation of HSV-1: first, the activity of 
the basic amino acid transporter and second, the quantity of 
lysine acquired through the diet.
Activity of the immune system in 
suppressing reactivation of HSV-1
Since 2005 evidence has been accumulating that points to 
CD8+ T cells in maintaining HSV-1 latency.24,25 Immuno-
senescence, or the decline of the immune system with age, 
appears to be related to involution of the thymus over time, 
with subsequent imbalance in T cell subtypes. There are 
no published reports specifically addressing the question 
of immunosenescence and HSV-1 reactivation in humans, 
although interestingly it has been reported that in mice the 
immune response to herpes simplex encephalitis is modulated 
by vitamin E.26 Vitamin E, of course, has long been the object 
of scientific interest in the search for a means to retard the 
progression of AD.
At present there is little that can be done to prevent or 
slow the process of immunosenescence. However, this does 
not necessarily apply to the lysine to arginine ratio in the 
CSF. The question arises, given that lysine is effective in sup-
pressing HSV-1 activation as manifested by herpes labialis, 
would it also suppress HSV-1 activation in the temporal and 
frontal cortices leading to AD? There are no data describ-
ing the prevalence of AD in older people who have taken 
at least 1,500 mg/day of lysine continuously over a period 
of years. However, given that it is known that diets rich in 
lysine and poor in arginine suppress HSV-1 replication, it 
would be instructive to know whether such diets are associ-
ated with lower prevalences of AD. The Mediterranean diet 
is one such diet. It emphasizes grains, but also emphasizes 
fruits, vegetables, cheese, yoghurt, and fish, all foods high 
in lysine and low in arginine.27 Perhaps more than any other 
food, weekly consumption of fish is associated with a lower 
risk of AD.28 This is generally attributed to omega-3 fatty 
acids in fish; however, it is also true that fish have a high 
lysine to arginine ratio.
A study published in 2001 described what may be the lowest 
incidence rates of AD ever found, in the Northern Indian rural 
community of Ballabgarh: 4.7 per 1,000 person-years, com-
pared with 17.5 per 1,000 person-years in the Monongahela 
Valley, Pennsylvania.29 The authors do not speculate on 
why this may be so. The residents of Ballabgarh are farm-
ers, remain physically active into older age, and obesity is 
essentially unknown. They also eat a diet proportionally 
high in dairy products, which have a very high lysine to 
arginine ratio.
Conversely, unlike fish and dairy products, tofu has a high 
arginine to lysine ratio. It was recently reported that high tofu 
intake among elderly Sudanese and Javanese, a population 
much like that of Ballabgarh, was unexpectedly associated 
with an increased risk of cognitive impairment.30
These observations are consistent with the hypothesis 
that if HSV-1 causes some cases of AD, a diet high in lysine 
relative to arginine may help prevent this from occurring 
by preventing reactivation of the latent virus in vulnerable 
regions of the brain.
Conclusion
To summarize, AD is a disease process, not a natural result 
of the aging process; HSV-1 is present in 70%–90% of the 
brains of older adults; HSV-1 has been identified in the tissue 
of patients with AD at autopsy; acute HSV-1 encephalitis 
affects many of the same regions of the brain that are affected 
by AD, and leads to long term memory loss; HSV-1 is known 
to reside in a latent form in the trigeminal nucleus, which 
projects to areas of the brain known to be affected by AD; there 
are indicators of an inflammatory process associated with AD, 
suggesting the possibility of an infectious etiology, possibly 
as a result of immunosenescence; activated HSV-1 virus is 
associated with formation of plaques and tangles, which are 
histologic hallmarks of AD; it is also associated with elevated 
cholesterol levels, also considered a risk factor for AD. Finally, 
there are indications that diets high in lysine and low in arginine 
may be associated with lower prevalences of AD.
This leads to the following hypothesis: HSV-1, latent 
in brain, becomes activated when in older age the ratio of 
lysine to arginine in the CSF favors arginine, providing a 
medium conducive to viral reactivation, and the process of 
immunosenescence releases the virus from immune system 
surveillance. Active HSV-1 then in turn causes AD. This 
process may be prevented or attenuated by increasing lysine, 
either in the diet, or as a supplement, or both. Studies of 
lysine treatment of herpes labialis suggest that supplements of 
1,500 mg twice a day or more are effective for this purpose.Neuropsychiatric Disease and Treatment
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Much of this, of course, is highly speculative. However, 
as noted above, the time may have come for thinking “outside 
of the box” in our approach to this terrible disease. The 
hypothesis as described above is highly testable, although it 
would require a very large study over many years to reach 
a definitive conclusion. Some would argue that it would be 
preferable to test the efficacy of the antivirals, rather than 
lysine supplementation. It cannot be argued, however, that 
the risk to patients posed by treatment with lysine is negli-
gible, and the potential benefit enormous: a safe, inexpensive 
approach to the prevention or attenuation of AD.
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